NMS · Biotechnology

GLUE (GLUE) Stock

$22.56 -0.97% NMS: GLUE Healthcare

Valuation

MetricValue
Price$22.56
Market Cap$1.91B
P/E Ratio-40.87
P/B Ratio6.46
P/S Ratio27.31
EPS (TTM)$-0.46
52-Week High$25.77
52-Week Low$4.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-16.74%
ROA-8.69%
ROCE-23.18%
Gross Margin-43.55%
Operating Margin-43.55%
Net Margin-3.03%
Debt/Equity0.07
Current Ratio6.14

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$76.0M$124.0M
Operating Profit$-73.0M$-112.0M$-143.0M$-81.0M$-54.0M
Net Profit$-74.0M$-109.0M$-135.0M$-73.0M$-39.0M
EPS$-1.59$-2.30$-2.63$-0.98$-0.46
Op Margin———-107.3%-43.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$366.0M$342.0M$304.0M$439.0M$449.0M
Total Liabilities$19.0M$71.0M$125.0M$216.0M$216.0M
Cash$346.0M$55.0M$128.0M$224.0M$130.0M
Borrowings$0$47.0M$46.0M$43.0M$39.0M

Latest News

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? Motley Fool · Jun 29, 2026 Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy Insider Monkey · Jun 3, 2026 Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire · May 20, 2026 Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention Simply Wall St. · May 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-59.0M$-92.0M$-44.0M$42.0M$-23.0M
Investing Cash Flow$-19.0M$-232.0M$70.0M$-48.0M$-107.0M
Financing Cash Flow$-3.0M$0$0$98.0M$0
Net Cash Flow$309.0M$-291.0M$72.0M$96.0M$-94.0M
Free Cash Flow$-69.0M$-105.0M$-63.0M$38.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-1.68%
Quick Ratio9.54
Interest Coverage—
Return 1Y286.41%
Return 3Y226.67%
Return 5Y22.70%

Ownership

Insiders Held0.58%
Institutions Held113.25%
Institutions Float Held113.91%
Institutional HolderSharesReport Date
NEA Management Company, LLC7,692,2982026-03-31
Price (T.Rowe) Associates Inc6,720,1882026-03-31
Blackrock Inc.5,637,6842026-03-31
TCG Crossover Management, LLC4,622,1512026-03-31
BVF Inc.4,460,8862026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
GERN $1.34 -4.29% 23.17 $859.64M 0.00%

About GLUE

GLUE is led by CEO Markus Warmuth, employs 142 people, headquartered in US, publicly traded since 2021.

GLUE stock trades at $22.56 with a market capitalization of $1.91B. The stock is valued at a price-to-earnings (P/E) ratio of -40.87, price-to-book of 6.46, price-to-sales of 27.31. Over the past 52 weeks the stock has ranged between $4.12 and $25.77, and currently trades 12.5% below its 52-week high.

On profitability, GLUE generates a return on equity (ROE) of -16.74%, return on capital employed of -23.18%, an operating margin of -43.55%, a net profit margin of -3.03%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides